Real-world study at ASCO GI shows Cadonilimab beats PD-1 inhibitors in 1st-line PD-L1-low gastric cancer. Akeso, Inc.presents findings.
In Hong Kong on January 13, 2026, Akeso, Inc. (9926.HK) revealed findings from a real-world analysis at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI). The study compared the effectiveness of cadonilimab in combination with chemotherapy to that of a PD-1 inhibitor along with [include more information].
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments